复发或转移性乳腺癌化疗方案给药计划——首选的单药

DOSING SCHEDULES FOR CHEMOTHERAPY REGIMENS FOR RECURRENT OR METASTATIC BREAST CANCERPreferred single agents:Anthracyclines:Doxorubicin●60-75

正文

DOSING SCHEDULES FOR CHEMOTHERAPY REGIMENS FOR RECURRENT OR METASTATIC BREAST CANCER

Preferred single agents:

Anthracyclines:

Doxorubicin

●60-75 mg/m2 IV day 1, Cycled every 21 days

or

●20 mg/m2 IV day 1 weekly

Pegylated liposomal encapsulated doxorubicin

●50 mg/m2 IV day 1

Cycled every 28 days.

Taxanes:

Paclitaxel

●175 mg/m2 IV day 1

Cycled every 21 days.

or

●80 mg/m2 IV day 1 weekly

Antimetabolites:

Capecitabine

●1000-1250 mg/m2 PO twice daily days 1-14

Cycled every 21 days.

Gemcitabine

●800-1200 mg/m2 IV days 1, 8, and 15

Cycled every 28 days.

Other microtubule inhibitors:

Vinorelbine

●25 mg/m2 IV day 1 weekly

Eribulin

●1.4 mg/m2 IV days 1 and 8

Cycled every 21 days.

Other single agents:

Cyclophosphamide

●50 mg PO daily on days 1-21

Cycled every 28 days.

Carboplatin

●AUC 6 IV on day 1

Cycled every 21-28 days.

Docetaxel

●60-100 mg/m2 IV day 1

Cycled every 21 days.

or

●35 mg/m2 IV weekly for 6 wks

Followed by a 2-week rest, then repeat

Albumin-bound paclitaxel

●100 mg/m2 or 150 mg/m2 IV days 1, 8, and 15

Cycled every 28 days.

or

●260 mg/m2 IV

Cycled every 21 days.

Cisplatin

●75 mg/m2 IV on day 1

Cycled every 21 days.

Epirubicin

●60-90 mg/m2 IV day 1

Cycled every 21 days.

Ixabepilone

●40 mg/m2 IV day 1

Cycled every 21 days.

The selection, dosing, and administration of anti-cancer agents and the management of associated toxicities are complex. Modifications of drug dose and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and individual patient variability, prior treatment, and comorbidity. The optimal delivery of anti-cancer agents therefore requires a health care delivery team experienced in the use of anti-cancer agents and the management of associated toxicities in patients with cancer.

复发或转移性乳腺癌化疗方案给药计划

首选的单药:

蒽环类抗生素:

阿霉素

●60-75mg/㎡ iv d1

每21天重复

●20mg/㎡ iv d1每周1次

聚乙二醇脂质体包裹阿霉素

●50mg/㎡IV d1

每28天为1周期。

紫杉烷类:

紫杉醇

●175mg/㎡ iv d1

每21天重复。

●80mg/㎡ iv d1每周1次

抗代谢药:

卡培他滨

●1000-1250mg/㎡ PO bid d1-14

每21天重复。

吉西他滨

●800-1200mg/㎡iv第1、8、15天

每28天为1周期。

其它微管抑制剂:

长春瑞滨

●25mg/㎡ iv d1每周1次

艾日布林

●1.4mg/㎡iv第1、8天

每21天重复。

其它的单药:

环磷酰胺

●50mg PO qd d1-21

每28天为1周期。

卡铂

●AUC 6 IV d1

每21-28天为1重复。

多西他赛

●60-100mg/㎡ iv d1

每21天重复。

●35mg/㎡ IV qw×6之后休息2周,然后重复

白蛋白结合型紫杉醇

●100mg/㎡或150mg/㎡iv第1、8、15天

每28天为1周期。

●260mg/㎡ iv

每21天重复。

顺铂

●75mg/㎡ IV d1

每21天重复。

表柔比星

●60-90mg/㎡ iv d1

每21天重复。

伊沙匹隆

●40mg/㎡ iv d1

每21天重复。

抗癌药物的选择、剂量和给药以及相关毒性的处理是复杂的。调整药物剂量与方案并启动支持治疗干预常常是必要的因为预期的毒性以及个体患者变异性、既往治疗及并存疾病。因此抗癌药物最佳的实施需要有在癌症患者中抗癌药物使用与相关毒性处理经验的保健医疗团队。

NCCN2015v3

医生推荐

 

高速代理IP全国工商数据库

多发性骨髓瘤,感染,糖尿病,便秘,感染,抑郁症,贫血,抽搐,脊柱侧弯,性病,。 诊疗文章网 

诊疗文章网 @ 2018